At OTT Group, we focus on decoding the molecular complexities of cancer using multi-omics integration, computational biology, and targeted therapeutics. Our research spans several key areas.
Investigating NRF2 pathway alterations in cancer.
Understanding its role in drug resistance and tumor metabolism.
Developing strategies to target NRF2-driven cancers.
Integrating genomic, transcriptomic, and proteomic data for biomarker discovery.
Analyzing mutations, CNVs, fusions, and structural variants across cancers.
Applying machine learning to predict cancer progression and therapy response.
Identifying clinically actionable mutations for personalized treatment.
Developing AI-driven models for patient stratification.
Exploring novel drug combinations for targeted therapy.
Investigating immune evasion and tumor-immune interactions.
Screening small molecules and repurposed drugs for new therapies.
Studying combination therapy approaches to overcome resistance.